{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:31:22Z","timestamp":1789486282238,"version":"build-2803163510"},"reference-count":80,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.14797\/mdcvj.1836","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:04:46Z","timestamp":1789477486000},"page":"28-39","source":"Crossref","is-referenced-by-count":0,"title":["Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention"],"prefix":"10.14797","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-3894","authenticated-orcid":false,"given":"Yakubu","family":"Bene-Alhasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4237-0267","authenticated-orcid":false,"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-881X","authenticated-orcid":false,"given":"Layla A.","family":"Abushamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-1730","authenticated-orcid":false,"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"issue":"2","key":"key20260915130440_B1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCRESAHA.116.309115","article-title":"Decline in cardiovascular mortality: possible causes and implications","volume":"120","year":"2017","journal-title":"Circ Res"},{"issue":"11","key":"key20260915130440_B2","first-page":"e596","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","year":"2019","journal-title":"Circulation"},{"issue":"18","key":"key20260915130440_B3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"key20260915130440_B4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","year":"2024","journal-title":"Eur J Intern Med"},{"key":"key20260915130440_B5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man--the LP system","volume":"59","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"1","key":"key20260915130440_B6","first-page":"e48","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"key20260915130440_B7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","year":"2013","journal-title":"J Intern Med"},{"issue":"6144","key":"key20260915130440_B8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","year":"1987","journal-title":"Nature"},{"issue":"22","key":"key20260915130440_B9","doi-asserted-by":"crossref","first-page":"11992","DOI":"10.1073\/pnas.94.22.11992","article-title":"Convergent evolution of apolipoprotein(a) in primates and hedgehog","volume":"94","year":"1997","journal-title":"Proc Nat Acad Sci"},{"issue":"6","key":"key20260915130440_B10","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI115248","article-title":"Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis","volume":"87","year":"1991","journal-title":"J Clin Invest"},{"issue":"1","key":"key20260915130440_B11","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels","volume":"41","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"key20260915130440_B12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","year":"2017","journal-title":"J Lipid Res"},{"issue":"4","key":"key20260915130440_B13","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1182\/blood.V90.4.1482","article-title":"Novel interaction of apolipoprotein(a) with \u03b2-2 glycoprotein i mediated by the kringle iv domain","volume":"90","year":"1997","journal-title":"Blood"},{"issue":"3","key":"key20260915130440_B14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"9","key":"key20260915130440_B15","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds","volume":"80","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20260915130440_B16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7555\/JBR.31.20160009","article-title":"Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role","volume":"32","year":"2018","journal-title":"J Biomed Res"},{"issue":"8","key":"key20260915130440_B17","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","year":"2016","journal-title":"J Lipid Res"},{"issue":"6562","key":"key20260915130440_B18","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abg8289","article-title":"Protein-coding repeat polymorphisms strongly shape diverse human phenotypes","volume":"373","year":"2021","journal-title":"Science"},{"issue":"6","key":"key20260915130440_B19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"key20260915130440_B20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1172\/JCI113849","article-title":"Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis","volume":"83","year":"1989","journal-title":"J Clin Invest"},{"key":"key20260915130440_B21","first-page":"3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","year":"2020","journal-title":"J Lipids"},{"issue":"5","key":"key20260915130440_B22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41569-023-00947-2","article-title":"Lipoprotein(a), platelet function and cardiovascular disease","volume":"21","year":"2024","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"key20260915130440_B23","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"3","key":"key20260915130440_B24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOL.0000000000000681","article-title":"Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?","volume":"31","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"key20260915130440_B25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20260915130440_B26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2023.09.836","article-title":"Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins","volume":"83","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"10289","key":"key20260915130440_B27","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"key20260915130440_B28","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/j.jacc.2024.03.367","article-title":"Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque","volume":"83","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"key20260915130440_B29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jacl.2023.06.002","article-title":"Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis","volume":"17","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"3","key":"key20260915130440_B30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of Lipoprotein(a) With Atherosclerotic Plaque Progression","volume":"79","year":"2022","journal-title":"JACC"},{"issue":"3","key":"key20260915130440_B31","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jacl.2025.02.007","article-title":"Association of lipoprotein(a) and coronary artery calcium with atherosclerotic cardiovascular disease","volume":"19","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"8","key":"key20260915130440_B32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jacc.2021.11.058","article-title":"Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk","volume":"79","year":"2022","journal-title":"JACC"},{"issue":"6","key":"key20260915130440_B33","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects","volume":"151","year":"2025","journal-title":"Circulation"},{"issue":"3","key":"key20260915130440_B34","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"7","key":"key20260915130440_B35","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","year":"2016","journal-title":"J Lipid Res"},{"issue":"11","key":"key20260915130440_B36","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwp043","article-title":"Lipid Changes During the Menopause Transition in Relation to Age and Weight","volume":"169","year":"2009","journal-title":"Am J Epidemiol"},{"issue":"12","key":"key20260915130440_B37","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups","volume":"139","year":"2019","journal-title":"Circulation"},{"key":"key20260915130440_B38","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","year":"2022","journal-title":"Atherosclerosis"},{"issue":"2","key":"key20260915130440_B39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0022-2275(20)30165-6","article-title":"Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians","volume":"43","year":"2002","journal-title":"J Lipid Res"},{"issue":"12","key":"key20260915130440_B40","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0022-2275(20)41895-4","article-title":"Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation","volume":"32","year":"1991","journal-title":"J Lipid Res"},{"issue":"5","key":"key20260915130440_B41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic Factors Explain a Major Fraction of the 50% Lower Lipoprotein(a) Concentrations in Finns","volume":"38","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"key20260915130440_B42","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-0004.1974.tb00657.x","article-title":"Lp(a) lipoprotein and pre-\u03b21-lipoprotein in patients with coronary heart disease","volume":"6","year":"1974","journal-title":"Clinical Genetics"},{"issue":"5","key":"key20260915130440_B43","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-0004.1997.tb04345.x","article-title":"Review: Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic\/thrombotic disease","volume":"52","year":"1997","journal-title":"Clinical Genetics"},{"issue":"7","key":"key20260915130440_B44","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jama.1996.03540070040028","article-title":"Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study","volume":"276","year":"1996","journal-title":"JAMA"},{"issue":"18","key":"key20260915130440_B45","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"key20260915130440_B46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population","volume":"4","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"22","key":"key20260915130440_B47","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","year":"2009","journal-title":"JAMA"},{"issue":"39","key":"key20260915130440_B48","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"key20260915130440_B49","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.STR.0000222666.21482.b6","article-title":"Lipoprotein(a) and Incident Ischemic Stroke","volume":"37","year":"2006","journal-title":"Stroke"},{"issue":"22","key":"key20260915130440_B50","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa001066","article-title":"Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly","volume":"349","year":"2003","journal-title":"New Engl J Med"},{"issue":"6","key":"key20260915130440_B51","article-title":"Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease","volume":"9","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"key20260915130440_B52","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel Risk Factors for Systemic AtherosclerosisA Comparison of C-Reactive Protein, Fibrinogen, Homocysteine, Lipoprotein(a), and Standard Cholesterol Screening as Predictors of Peripheral Arterial Disease","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"17","key":"key20260915130440_B53","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis","volume":"73","year":"2019","journal-title":"JACC"},{"issue":"5","key":"key20260915130440_B54","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population","volume":"63","year":"2014","journal-title":"JACC"},{"issue":"6","key":"key20260915130440_B55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic Associations with Valvular Calcification and Aortic Stenosis","volume":"368","year":"2013","journal-title":"New Engl J Med"},{"issue":"11","key":"key20260915130440_B56","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis","volume":"66","year":"2015","journal-title":"JACC"},{"issue":"6","key":"key20260915130440_B57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An Exploratory Analysis of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial","volume":"5","year":"2020","journal-title":"JAMA Cardiol"},{"key":"key20260915130440_B58","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?","volume":"349","year":"2022","journal-title":"Atherosclerosis"},{"key":"key20260915130440_B59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","year":"2019","journal-title":"Atherosclerosis"},{"issue":"8","key":"key20260915130440_B60","doi-asserted-by":"crossref","first-page":"100239","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","year":"2022","journal-title":"J Lipid Res"},{"key":"key20260915130440_B61","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2021.11.053","article-title":"Measurement of lipoprotein(a): a once in a lifetime opportunity","volume":"79","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20260915130440_B62","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-Traceable Reference Measurement System for Seven Serum Apolipoproteins Using Bottom-Up Quantitative Proteomics: Conceptual Approach Enabled by Cross-Disciplinary\/Cross-Sector Collaboration","volume":"67","year":"2021","journal-title":"Clin Chem"},{"issue":"17","key":"key20260915130440_B63","doi-asserted-by":"crossref","first-page":"e1154","DOI":"10.1161\/CIR.0000000000001423","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Writing Committee Members","year":"2026","journal-title":"Circulation"},{"issue":"7","key":"key20260915130440_B64","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jacl.2026.05.226","article-title":"Correlation between serum and plasma lipoprotein(a) measurements: ARIC Study","volume":"20","year":"2026","journal-title":"J Clin Lipidol"},{"issue":"1","key":"key20260915130440_B65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"key20260915130440_B66","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","year":"2021","journal-title":"Can J Cardiol"},{"key":"key20260915130440_B67","first-page":"409","article-title":"Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis","year":"2025","journal-title":"Atherosclerosis"},{"key":"key20260915130440_B68","doi-asserted-by":"crossref","first-page":"120794","DOI":"10.1016\/j.atherosclerosis.2026.120794","article-title":"Persistent gaps in management and risk factor control among patients with atherosclerotic cardiovascular disease: All of Us Research Program","volume":"418","year":"2026","journal-title":"Atherosclerosis"},{"issue":"1","key":"key20260915130440_B69","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacl.2017.10.024","article-title":"Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials","volume":"12","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"21","key":"key20260915130440_B70","article-title":"Temporal Trends in Lipoprotein(a) Concentrations: The Atherosclerosis Risk in Communities Study","volume":"11","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"key20260915130440_B71","first-page":"408","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","year":"2025","journal-title":"Atherosclerosis"},{"issue":"11","key":"key20260915130440_B72","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","year":"2012","journal-title":"J Lipid Res"},{"issue":"3","key":"key20260915130440_B73","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"New Engl J Med"},{"key":"key20260915130440_B74","doi-asserted-by":"crossref","first-page":"120670","DOI":"10.1016\/j.atherosclerosis.2026.120670","article-title":"The evolving therapeutic landscape of PCSK9 inhibition","volume":"414","year":"2026","journal-title":"Atherosclerosis"},{"issue":"9","key":"key20260915130440_B75","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","article-title":"AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy","volume":"128","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"key20260915130440_B76","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"key20260915130440_B77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome","volume":"75","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"key20260915130440_B78","doi-asserted-by":"crossref","first-page":"100641","DOI":"10.1016\/j.ajpc.2024.100641","article-title":"Lipoprotein(a): Emerging insights and therapeutics","volume":"18","year":"2024","journal-title":"Am J Prev Cardiol"},{"issue":"44","key":"key20260915130440_B79","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1093\/eurheartj\/ehaf606","article-title":"The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications","volume":"46","year":"2025","journal-title":"Eur Heart J"},{"issue":"3","key":"key20260915130440_B80","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"333","year":"2025","journal-title":"JAMA"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:04:55Z","timestamp":1789477495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1836\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["10.14797\/mdcvj.1836"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1836","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}